UC Davis-led trial of Zynlonta combination in DLBCL marked suspended as of Nov. 16 updateNov 16Trial updateADC Therapeutics SAloncastuximab tesirine
Genmab's Phase 3 China DLBCL trial of epcoritamab posts results, listed active not recruitingNov 10Trial updateAbbVieepcoritamab-bysp
ADC Therapeutics reports Q3 2026 results, restructuring extends cash runway into 2029Nov 9Quarterly updateADC Therapeutics SAloncastuximab tesirine
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Genmab's EPCORE DLBCL-1 Phase 3 trial posts results after primary completion in October 2026Nov 3Trial updateAbbVieepcoritamab-bysp
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Incyte's radiolabeled INCB161734 mass balance study active, not recruitingOct 16Weekly roundup, 4 itemsINCA33890INCB161734
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruitsOct 15Weekly roundup, 5 itemsBoehringer Ingelheimempagliflozin
University of Washington trial of Rylaze in adult ALL remains suspended for safety reviewOct 5Clinical readoutasparaginase erwinia chrysanthemi (recombinant)-rywnGenmab A/SUpdated
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trialOct 2Weekly roundup, 5 itemsAmgenapremilastUpdated
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
Rocket Pharmaceuticals says FDA aligns on Danon disease pivotal trial pathSep 15Clinical readoutRocket Pharmaceuticals, Inc.
Fate Therapeutics registers Phase 1/2 trial of FT839 across five autoimmune diseasesSep 2Trial updateFate TherapeuticsFT839
Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completionAug 18Trial updateglofitamabprednisone
Cellectar registers Phase 3 trial comparing iopofosine I 131 to R-CD in Waldenstrom'sAug 14Trial updateCellectar Biosciences, Inc.
Artiva reports Q2 2026 results, RMAT for AlloNK in refractory RA, Phase 3 planAug 6Quarterly updateArtiva Biotherapeutics, Inc.
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax
AbbVie to acquire Apogee Therapeutics, updates 2026 EPS guidance amid Q2 resultsJul 31Quarterly updateAbbVie
Trial registered for tafasitamab plus rituximab in newly diagnosed follicular lymphomaJul 28Trial updateIncyte Corporationrituximab